Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2025-09-26 00:00:00 ET · period of report 2025-09-25 · accession 0001193125-25-220950 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-26 | 2025-09-25 | PHAT | Basta Steven L | Pres, CEO, Dir | M - OptEx | $0.00 | +90.0K | 90.0K | New | $0 |
| D | 2025-09-26 | 2025-09-25 | PHAT | Basta Steven L | Pres, CEO, Dir | F - Tax | $11.66 | -48.4K | 41.6K | -54% | -$564.1K |
| D | 2025-09-26 | 2025-09-25 | PHAT | Basta Steven L | Pres, CEO, Dir | M - OptEx | $0.00 | -90.0K | 270.0K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-25 | M | A | 90,000 | $0.00 | 90,000 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-25 | F | D | 48,375 | $11.66 | 41,625 | D | — | — | |
| 3 | Derivative | Performance Shares | 2025-09-25 | M | D | 90,000 | $0.00 | 270,000 | D | $0.00 · — to — | 90,000 Common Stock | (F2) Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. (F3) On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved. |